Solventum 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Solventum reported Q3 sales of $1.95 billion, down 7% on a reported basis and down 2.8% organically; foreign currency benefited reported growth by 30 basis points, while acquisitions and divestitures were a 450 basis point headwind.
- Organic sales included a $125 million reversal of ERP-related advance orders, a headwind of approximately 630 basis points; normalized organic growth was approximately 4%, including 90 basis points of SKU rationalization headwinds.
- Med-Surg sales were $1.2 billion, down 2.8% organically; Advanced Wound Care grew 1.5%, and Acera contributed $35 million to reported sales and grew 35%.
- Dental Solutions sales were $317 million, down 7.4% organically, while Health Information Systems sales were $356 million, up 4.4% organically.
- Gross margin was 57.1%, up 120 basis points year over year; operating income was $387 million, with a 19.9% operating margin, down 70 basis points year over year.
- EPS was $1.45, including an approximately $0.35 impact from the reversal of Q2 ERP-related advance orders.
- Q3 free cash flow increased by $97 million; excluding separation-related activities and portfolio optimization, free cash flow would have been $334 million.
- Solventum ended the quarter with $451 million in cash and equivalents and net debt of $4.6 billion, and repurchased approximately 570,000 shares for nearly $50 million.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. My name is Carly, and I will be your conference call operator today. I would like to welcome everyone to Solventum's third quarter 2026 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Investor Relations and Finance Communications.
Please proceed. Thank you. Good afternoon, and welcome to Solventum's third quarter fiscal year 2026 earnings call.
Joining me on today's call are Chief Executive Officer Bryan Hanson and Chief Financial Officer Wayde McMillan. A replay of today's earnings call will be available later today on the Investor Relations section of our corporate website. The earnings press release and the presentation are both available there now. During today's call, our discussion and any comments we make will be on a non-GAAP basis unless they are specifically called out as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. Please review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers.
Our discussion on today's call will include forward-looking statements, including but not limited to expectations about our future financial and operating performance. These statements are made based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Following our prepared remarks, we will hold a question-and-answer session. For the Q&A portion of today's call, I would like to remind our analysts to please limit yourself to one question. If you have additional questions, you can rejoin the Q&A queue. I would like to now hand the call over to Bryan.
All right. Thanks, Amy, and thanks to everyone for joining us today. Let me just start by saying that in the third quarter, we executed the largest and most complex ERP cutover in the history of this company. Thankfully, it was also the last on our path to full separation. I can tell you from experience that a cutover at that scale is never seamless, and ours was no exception. But the mitigation plan that we built, it held, and this team delivered through it. To our customers, I want to say thank you for your partnership. You leaned in and worked with our teams, and that is what kept product moving to the patients who needed them. To our team specifically, this was a significant cross-functional effort. We had supply chain, IT, commercial, customer service, quality, finance, all pulling in the same direction.
And that kind of team dynamic under that kind of team pressure isn't something you can just install. You either have it or you don't. We clearly have it. Speaking of having it, let's get into the quarter. All key financial metrics were in line or ahead of our expectations, with organic growth and EPS both above plan. As we communicated in August, these results reflect the advanced orders reversing back out of the quarter following the ERP cutover. Once again, this team has proven that the say-do equation that we value so much is alive and well regardless of the challenges around us. As solid as the quarter was, the progress on our transformation has to be just as encouraged. Just a quick reminder, we're running a three-phase transformation: stabilize and separate the business, reposition for profitable growth, and optimize the portfolio.
As always, those phases are not sequential. They're running concurrently. Let me start with separation because there's a pretty big headline here. With the Americas cutover behind us, separation is now more than 90% complete. We still have work to do to close out the rest, but the key message here, the important message is that the structural work, the risky work, that's done. This will also significantly strengthen our free cash flow as separation costs roll off, which will be reflected in our Q4 performance. I can just say this is a significant milestone for Solventum, and I'm extremely proud of the team for getting us here. Related to that, and this is also important, we successfully renegotiated our raw material supply agreement with 3M, aligning on a long-term supply agreement that is better for both companies.
There are two things I want you to take away from this for Solventum. First, it strengthens supply continuity for the critical materials that leverage our intellectual property. Second, it's an important variable in our ability to improve year-over-year margins in 2027, particularly given the known tariff headwinds created by the one-time tariff refund we received in 2026. It clearly increases confidence in our Holdco 2028 LRP target of 23%-25%. Moving on to portfolio optimization, and specifically HIS, with a focus on continuing to execute our portfolio optimization strategy. In August, we announced our intent to separate our Health Information Systems business. As I said last quarter, our focus here is clear. We're going to run the most shareholder-friendly separation process that we can, where both businesses have enhanced strategic clarity and more focused investment.
As a result, we're looking at both spin and sale options and taking the appropriate actions to move both of those options forward. When it comes to proceeds from the separation path chosen, we have two primary areas of focus. The first is paying down debt to hold our credit rating, and the second is returning capital to shareholders. When it comes to RemainCo, we will have a very focused and compelling business. Remember that four of our five growth drivers, as well as the Acera acquisition, will remain with Solventum. On a smaller base, their impact will be magnified, as will future tuck-in acquisitions. The largest majority of our go-forward margin expansion levers, well, they sit inside of the RemainCo business. So our margin improvement opportunity off a new starting point will be even more compelling.
But as I've said before, portfolio moves are only part of the story. The engine here is organic growth, and our growth driver areas continue to fuel the growth that we designed them to. As a quick reminder, there are five growth drivers: negative pressure wound therapy, IV site management, sterilization assurance, core restoratives, and revenue cycle management. Together, they represent a multi-billion dollar opportunity. For much of this opportunity, we're not trying to break into new accounts and displace an incumbent. We're simply going to customers who already trust us and showing them, with data, a better standard of care that they're not using yet. That's fundamentally a lower-risk path to growth, and it's a big part of why we have the conviction we do on the long-range plan. Let me just make it real with one example. This quarter, I'll talk about our V.A.C.
system, which is our proprietary negative pressure wound therapy technology, and I'll look at the U.S. In the U.S. alone, complex and chronic wounds affect roughly one in six Medicare beneficiaries. One in six Medicare beneficiaries. Depending on whose study you read, that's about 10.5 million people at a cost to Medicare north of $20 billion per year. Those are big numbers, and as we know, big numbers tend to go in one ear and out the other, so let me describe it this way. For a patient with a diabetic foot ulcer, five-year mortality runs somewhere between 30% and 55%. Once a patient progresses to major amputation, more than half will not survive the next five years. Studies with V.A.C. Therapy show wounds are ready for closure almost twice as fast. Studies also show a 60% reduction in amputations versus non-V.A.C. treatments, and yet V.A.C.
Therapy is only used about 10% of the time, so roughly 90% of this opportunity is still in front of us. It's not sitting behind a technology gap. It's not sitting behind an evidence gap. The studies are clear. The therapy works. One of the major reasons it doesn't get used more often is just friction. It's the workflow complexity and the time of application on a busy, short-staffed unit. That's why we've launched the V.A.C. Peel and Place dressing, to engineer the complexity and the time out of the application. Peel and Place shows a 61% reduction in application time, and it can stay on for up to seven days versus currently being changed every two to three days, significantly reducing time and complexity. Our innovation did not just enhance the clinical workflow.
The design improves the patient experience, with 10 out of 10 patients reporting no pain upon removal. I can tell you, for busy care teams and their patients, simpler application, fewer dressing changes, and less pain for removal make an established therapy easier to incorporate into everyday care. So think about this. Same customer, same call point, therapy we already have with outcome studies already in hand for patients who already qualify for it, but nine times out of 10 not getting it, and we intend to close that gap. Of course, attractive markets aren't enough. You also need to ensure cross-functional focus, particularly across your R&D engine, commercial, and market development infrastructure, and that's exactly what our growth driver strategy accomplishes. In MedSurg, three of our five growth drivers live here. All three continue to contribute.
In the area that I just talked about, negative pressure wound therapy, our V.A.C. Peel and Place dressing continues to ramp, and Prevena keeps building on the single-use side of the equation. In IV site management, we continue to gain traction behind Tegaderm CHG and our Curos caps, which really creates our belt-and-suspenders approach to reducing catheter-related bloodstream infections. On sterilization assurance, we are now fully in market with the three new Attest products we launched earlier this year. On Acera, the integration continues to be on track, and the business delivered its best quarter on record. We also received the 510(k) clearance for the combined use of Restrata with the V.A.C. Therapy faster than we expected, and it is the first of its kind. The commercial benefit here is every bit as important as the clinical one.
It lets us now co-market the technologies and put our combined commercial organizations behind them. That is exactly the leverage we underwrote when we acquired Acera. In dental, core restoratives and new product launches are doing the heavy lifting, with Clinpro Clear, the Filtek Easy Match family of launches, our Filtek Composite Warmer, and Clarity aligner attachments continuing to gain traction. We also moved forward with the limited launch phase of our Clarity Composite Veneers, which is obviously focused on the aesthetic space, with early market access delivering 1,000-plus transformed smiles, giving us strong validation ahead of the full launch expected in the first part of 2027. In HIS, our revenue cycle management continues to perform, with 360 Encompass adoption expanding, our AI-driven autonomous coding applications gaining traction, and continued international expansion.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
